Fig. 1From: Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trialThe flow diagram of patient enrollment for the phase II clinical trial of famitinib versus placebo in the treatment of refractory metastatic colorectal cancer (mCRC)Back to article page
